» Articles » PMID: 28869519

Differences in Sulfotyrosine Binding Amongst CXCR1 and CXCR2 Chemokine Ligands

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Sep 5
PMID 28869519
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Tyrosine sulfation, a post-translational modification found on many chemokine receptors, typically increases receptor affinity for the chemokine ligand. A previous bioinformatics analysis suggested that a sulfotyrosine (sY)-binding site on the surface of the chemokine CXCL12 may be conserved throughout the chemokine family. However, the extent to which receptor tyrosine sulfation contributes to chemokine binding has been examined in only a few instances. Computational solvent mapping correctly identified the conserved sulfotyrosine-binding sites on CXCL12 and CCL21 detected by nuclear magnetic resonance (NMR) spectroscopy, demonstrating its utility for hot spot analysis in the chemokine family. In this study, we analyzed five chemokines that bind to CXCR2, a subset of which also bind to CXCR1, to identify hot spots that could participate in receptor binding. A cleft containing the predicted sulfotyrosine-binding pocket was identified as a principal hot spot for ligand binding on the structures of CXCL1, CXCL2, CXCL7, and CXCL8, but not CXCL5. Sulfotyrosine titrations monitored via NMR spectroscopy showed specific binding to CXCL8, but not to CXCL5, which is consistent with the predictions from the computational solvent mapping. The lack of CXCL5-sulfotyrosine interaction and the presence of CXCL8-sulfotyrosine binding suggests a role for receptor post-translational modifications regulating ligand selectivity.

Citing Articles

Trapped in the NETs: Multiple Roles of Platelets in the Vascular Complications Associated with Neutrophil Extracellular Traps.

Sennett C, Pula G Cells. 2025; 14(5).

PMID: 40072064 PMC: 11898727. DOI: 10.3390/cells14050335.


Selection Pressure Regulates the Evolution-Structure-Function Paradigm of Monocyte Chemoattractant Protein Family.

Nagar N, Gulati K, Poluri K J Mol Evol. 2025; .

PMID: 39907741 DOI: 10.1007/s00239-025-10235-x.


High-affinity ELR+ chemokine ligands show G protein bias over β-arrestin recruitment and receptor internalization in CXCR1 signaling.

Boon K, Vanalken N, Szpakowska M, Chevigne A, Schols D, Loy T J Biol Chem. 2024; 301(1):108044.

PMID: 39615686 PMC: 11732455. DOI: 10.1016/j.jbc.2024.108044.


The TRIM33 Bromodomain Recognizes Histone Lysine Lactylation.

Nunez R, Sidlowski P, Steen E, Wynia-Smith S, Sprague D, Keyes R ACS Chem Biol. 2024; 19(12):2418-2428.

PMID: 39556662 PMC: 11706526. DOI: 10.1021/acschembio.4c00248.


Sulfoproteomics Workflow with Precursor Ion Accurate Mass Shift Analysis Reveals Novel Tyrosine Sulfoproteins in the Golgi.

Kweon H, Kong A, Hersberger K, Huang S, Nesvizhskii A, Wang Y J Proteome Res. 2023; 23(1):71-83.

PMID: 38112105 PMC: 11218929. DOI: 10.1021/acs.jproteome.3c00323.


References
1.
Proost P, De Wolf-Peeters C, Conings R, Opdenakker G, Billiau A, Van Damme J . Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J Immunol. 1993; 150(3):1000-10. View

2.
Jiang S, Liou J, Chang C, Chung Y, Lin L, Hsu H . Peptides derived from CXCL8 based on in silico analysis inhibit CXCL8 interactions with its receptor CXCR1. Sci Rep. 2015; 5:18638. PMC: 4686899. DOI: 10.1038/srep18638. View

3.
Veldkamp C, Seibert C, Peterson F, Sakmar T, Volkman B . Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12). J Mol Biol. 2006; 359(5):1400-9. PMC: 2670582. DOI: 10.1016/j.jmb.2006.04.052. View

4.
Sepuru K, Rajarathnam K . CXCL1/MGSA Is a Novel Glycosaminoglycan (GAG)-binding Chemokine: STRUCTURAL EVIDENCE FOR TWO DISTINCT NON-OVERLAPPING BINDING DOMAINS. J Biol Chem. 2016; 291(8):4247-55. PMC: 4759198. DOI: 10.1074/jbc.M115.697888. View

5.
Ludeman J, Stone M . The structural role of receptor tyrosine sulfation in chemokine recognition. Br J Pharmacol. 2013; 171(5):1167-79. PMC: 3952796. DOI: 10.1111/bph.12455. View